Interferon-γ and monoclonal antibody 131I-labeled CC49: Outcomes in patients with androgen-independent prostate cancer

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 643-651

  Slovin, Susan F ^a,c   Scher, Howard I ^a,c   Divgi, Chaitan R ^a   Reuter, Victor ^a   Sgouros, George ^a   Moore, Malcolm ^a   Weingard, Kerri ^a,c   Pettengall, Ruth ^a   Imbriaco, Massimo ^a   El Shirbiny, Ayda ^a   Finn, Ron ^a   Bronstein, Jeff ^a   Brett, Chris ^a,c   Milenic, Diane ^b   Dnistrian, Ann ^a   Shapiro, Lisa ^a,c   Schlom, Jeff ^a,b   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BINDING SITE; CLINICAL ARTICLE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR LOCALIZATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BONE AND BONES; BONE MARROW; COMBINED MODALITY THERAPY; GLYCOPROTEINS; HUMANS; INTERFERON TYPE II; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 14444269199     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Haq, M., Goltzman, D., Tremblay, G., and Brodt, P. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res., 52: 4613-4619, 1992.
2. Berrettoni, B. A., and Carter, J. R. Mechanisms of cancer metastasis to bone. J. Bone Joint Surg., 68-A: 308-312, 1986.
3. Scher, H. I., and Chung, L. W. K. Bone metastases: biology and therapy. Semin. Oncol., 21: 630-656, 1994.
4. MacLean, G. D., Reddish, M., Koganti, R. R., Wong, T., Gandhi, S., Smolenski, M., Samuel, J., Nabholtz, J. M., and Longenecker, B. M. Immunization of breast cancer patients using a synthetic sialyl-TN glycocongjugate plus detox adjuvant. Cancer Immunol. Immunother., 36: 215-222, 1993.
5. Stramignoni, D., Bowen, R., Atkinson, B., and Schlom, J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int. J. Cancer, 31: 543-552, 1983.
6. Szpak, C. A., Johnston, W. W., Roggli, V., Kolbeck, J., Lottich, S. C., Vollmer, R., et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by monoclonal antibody (B72.3). Am. J. Pathol., 122: 252-260, 1986.
7. Divgi, C. R., Scott, A. M., Dantis, L., Capitelli, P., Siler, K., Hilton, S., Finn, R. D., Kemeny, N., Kelsen, D., and Kostakoglu, L. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J. Nucl. Med., 36: 586-592, 1995.
8. Myers, R. B., Meredith, R. F., Schlom, J., LoBuglio, A. F., Bueschen, A. H., Wheeler, R. H., Stockard, C. R., and Grizzle, W. E. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J. Urol., 152: 243-246, 1994.
9. Theodoulou, M., Reuter, V., Drobnjak, M., Kelly, K., and Scher, H. I. Epidermal growth factor receptor (EGFr) and TAG-72 expression in hormone-refractory (HR) patients with locally recurrent and metastatic prostate (PR) cancer. J. Urol., 153: 485, 1995.
10. Brenner, P. C., Rettig, W. J., Sanz-Moncasi, M. P., Reuter, V., Aprikian, A., Old, L. J., Fair, W. R., and Garin-Chesa, P. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J. Urol., 153: 1575-1579, 1995.
11. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Schlom, J., Russell, C. D., Liu, T., and LoBuglio, A. F. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med., 35: 1017-1022, 1994.
12. Van, X., Wong, J. Y. C., Esteban, J. M., Kuhn, J. A., Beatty, B. G., Beatty, J. D., et al. Effects of recombinant human γ-interferon on carcinoembryonic antigen expression of human colon cancer cells. J. Immunother., 11: 77-84, 1991.
13. 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J. Natl. Cancer Inst. (Bethesda), 80: 160-165, 1984.
14. Greiner, J. W., Guadagni, F., Goldstein, D., Smalley, R. V., Borden, E. C., Simpson, J. F., Molinolo, A., and Schlom, J. Intraperitoneal administration of interferon-γ to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J. Clin. Oncol., 10: 735-746, 1992.
15. Greiner, J. W., Guadagni, F., Goldstein, D., Borden, E. C., Ritts, R. E., Witt, P., LoBuglio, A. F., Saleh, M. N. and Schlom, J. Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons. Cancer Res., 51: 4155-4163, 1991.
16. Scher, H. L, Mazumdar, M., and Kelly, W. K. Clinical trials in relapsed prostate cancer: defining the target. J. Natl. Cancer Inst. (Bethesda), 88: 1623-1634, 1996.
17. Scher, H. I., and Yagoda, A. Clinical trials in prostatic cancer: methodology and controversies. In: A. W. Bruce and J. Trachtenberg (eds.), Adenocarcinoma of the Prostate, pp. 197-220. New York: Springer-Verlag New York, Inc., 1987.
18. Smith, P. H., Bono, A., Calais da Silva, F., Debruyne, F., Denis, L., Robinson, P., Sylvester, R., and Armitage, T. G. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer (Phila.), 66: 1009-1016, 1990.
19. Sabbatini, P., Yeung, H., Imbriaco, M., Mazumdar, M., Vlamis, V., Kelly, K., et al. The correlation of serial bone scintigraphy and PSA determinations in patients (Pts) with androgen independent prostate cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 15: 254, 1996.
20. International Commission on Radiation Protection. Report of the Task Group on Reference Man, Publ. No. 23. Washington, D.C.: ICRP.
21. 131I-CC49 in patients with hormone-independent prostate cancer pretreated with gamma-interferon. J. Nucl. Med., in press, 1998.
22. . Ferroni, P., Milenic, D. E., Roselli, M., Carrasquillo, J. A., Raubitschek, A., Schlom, J., and Colcher, D. Potential for artifacts in monitoring for the detection of tumor associated antigens (TAG-72 and CEA) in serum from patients undergoing Mab-based diagnostic and therapeutic protocols. Int. J. Biol. Mark., 5: 166-176, 1990.
23. Paterson, A. J., Schlom, J., Sears, H. F., Bennett, J., and Colcher, D. A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. Int. J. Cancer, 37: 659-666, 1986.
24. Klug, T. L., Sattler, M. A., Colcher, D., and Schlom, J. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). Int. J. Cancer, 38: 661-669, 1986.
25. Shapiro, F., Yao, T., Raptis, G., Reich, L., Norton, L., and Moore, M. A. S. Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer. Blood, 84: 3567-3574, 1994.
26. Castro-Malaspina, H., Gay, R. E., Resnick, G., Kapoor, N., Meyers, P., Chiarieri, D., et al. Characterization of human bone marrow fibroblast colon-forming cells (CFU-F) and their progeny. Blood, 56: 289-301, 1980.
27. Pettengall, R., Testa, N. G., Swindell, R., Crowther, D., Dexter, T. M. Transplantation of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood, 82: 2239-2238, 1993.
28. Rafii, S., Shapiro, F., Pettengall, R., et al. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood, 86: 3353-3364, 1995.
29. Snoeck, H. W., van Bockstaele, D. R., Nys, G., Lenjou, M., Lardon, F., Haenen, L., et al. Interferon gamma selectively inhibits very primitive CD342+CD38-and not more mature CD34+CD38+ human hematopoietic progenitor cells. J. Exp. Med., 180: 1177-1182, 1994.
30. Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., et al. Results of a randomized Phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 25: 805-813, 1993.
31. Robinson, R. G., Preston, D. F., Schiefelbein, M., and Baxter, K. G. Strontium-89 therapy for the palliation of pain due to osseous metastases. J. Am. Med. Assoc., 274: 420-424, 1995.
32. Gabrilove, J. L., Jakubowski, A., Scher, H., Sternberg, C., Wong, G., Grous, J., Yagoda, A., Fain, K., and Moore, M. A. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N. Engl. J. Med., 318: 1414-1422, 1988.
33. Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., et al. Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 25: 805-813, 1993.
34. Lewington, V. J., McEwan, A. J., Ackery, D. M., Bayly, R. J., Keeling, D. H., Macleod, P. M., Porter, A. T., and Zivanovic, M. A. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur. J. Cancer, 27: 954-958, 1991.
35. Elomaa, I., Blomqvist, C., Grohn, P., Prokka, K., Kaitento, A. L., Selender, K., et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet, ii: 865-868, 1988.
36. Stoldt, H. S., Aftab, F., Chinol, M., Paganelli, G., Luca, F., Testori, A., and Geraghty, J. G. Pretargeting strategies for radio-immunoguided tumor localization and therapy. Eur. J. Cancer, 33: 186-192, 1997.